VANCOUVER, British Columbia--Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a biopharmaceutical company dedicated to discovering, developing and canadian healthcare viagra commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), announced that it will hold a conference call and webcast on Thursday, March 12, 2015 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a corporate update and report on its financial results for the fourth quarter and viagra tablet viagra usa year ended December 31, 2014.
MINNEAPOLIS--The Colon Cancer Coalition kicked-off a jam-packed Colon Cancer Awareness Month by basking in the blue lights of the 35W Bridge in Minneapolis. But to the colon cancer community, the color blue on such a prominent landmark means more.
MADISON, Wis.--Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL), a developer and 6thnde.com/prednisone-online-overnight/ producer of fully functioning human cells in industrial quantities to precise specifications, today reported financial results for the fourth quarter and for the fiscal year ended December 31, 2014.
PORTLAND, Ore.--Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today reported its financial results for the quarter and year ended December 31, 2014 and provided a business update.
BERKELEY, Calif.--XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and viagra soft development of therapeutic antibodies, announced today the results from its Phase 1 first-in-human study of XOMA 358, an allosteric modulating monoclonal antibody that binds to insulin receptors and cheap cialis online canadian pharmacy attenuates insulin action, will be presented at the Endocrine Society's 97th Annual Meeting, taking place from March 5-8, 2015, in San Diego, California.
DUBLIN, Ireland--Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and discount canadian pharmacy commercialization of novel protein immunotherapy programs, today reported financial results for the fourth quarter and full year ended December 31, 2014 and provided 2015 financial guidance and an update on its lead programs.
EXTON, Pa.--Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will report fourth quarter and full year 2014 financial and operating results on March 13, 2015.
SOUTH SAN FRANCISCO, Calif.--Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Julie Hambleton, M.D., Chief Medical Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 12, 2015 at 1:05 PM Eastern Daylight Time.
SOUTH SAN FRANCISCO, Calif.--Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today an exclusive global license agreement with TransTech Pharma, a clinical stage pharmaceutical company, granting Calithera exclusive world-wide rights to research, develop and commercialize TransTech's portfolio of hexokinase II inhibitors.